Miloš Grujić

Dr. Miloš Grujić

Clinical Oncology, University of Kragujevac, Faculty of medical sciences, Kragujevac, Serbia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ZBZineddine Belabaci
Zineddine Belabaci
GBGiulio Brignoli
Giulio Brignoli
TZThomas Zilli
Thomas Zilli
Miloš GrujićMiloš Grujić
Miloš Grujić
IMIssa Mohamad
Issa Mohamad
AAAli Afshar-Oromieh
Ali Afshar-Oromieh
Background: Targeted radionuclide therapy (TRT) has become a standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177 labeled PSMA radioligand therapy ([¹⁷⁷Lu]Lu-PSMA) is an established and effective treatment option, while [²²⁵Ac]Ac-PSMA shows promise in refractory cases. The tandem use of [225Ac] Ac and [177Lu] Lu-labeled PSMA ligands is currently being explored to harness the complementary advantages of both isotopes. This meta-analysis investigates the efficacy and safety of [²²⁵Ac]Ac -/[¹⁷⁷Lu]Lu-PSMA radioligand therapy (RLT) in patients with mCRPC. Methods: This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A comprehensive literature search was performed in PubMed, EMBASE, Web of Science (WOS), and Scopus databases, covering all records from inception through March 2025. The primary endpoints focused on therapeutic efficacy, assessed through PSA-based biochemical responses. These included any PSA decline, a PSA decline of more than 50% from baseline, stable disease (defined as a PSA increase of < 25% PSA increase or a decrease of < 50%), and progressive disease (defined as an increase of ≥ 25% PSA) following tandem 225Ac-/177Lu-PSMA tandem RLT. Secondary endpoints included overall survival (OS) and treatment-related adverse events. A random-effects model was used to generate pooled proportions through meta-analysis. Results: Eight studies, including a total of 323 patients treated with [²²⁵Ac]-/[¹⁷⁷Lu]-PSMA combination therapy, were analyzed. The pooled response rates showed that 47% (95% CI: 37%–56%) experienced a PSA decline greater than 50%, while 78% (95% CI: 70%–86%) had any measurable PSA decline. The estimated median OS was 11.8 months (95% CI: 9.0–14.6 months). Severe toxicities were infrequent; the most common severe grade ≥ 3 adverse events were anemia (10%) and thrombocytopenia (6%). No cases of grade ≥ 3 xerostomia were reported. Conclusion: [²²⁵Ac]Ac-/[¹⁷⁷Lu]Lu-PSMA RLT shows encouraging activity and manageable safety in patients with advanced mCRPC. Given the retrospective nature of the available evidence and limited data, these findings should be further evaluated in prospective trials to determine long-term efficacy and survival outcomes.

29 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Miloš GrujićMiloš Grujić
Miloš Grujić
SVStanislav Volchenkov
Stanislav Volchenkov
AAAidos Akhmetali
Aidos Akhmetali
MRMarija Zivkovic Radojevic
Marija Zivkovic Radojevic
NMNeda Milosavljević
Neda Milosavljević
MMMladen Marinkovic
Mladen Marinkovic
Background/Objectives: Ultra-low-dose radiotherapy (ULD-RT), an ultra-low-dose regimen delivering 4 Gy in two fractions, has emerged as a promising treatment for indolent ocular adnexal lymphoma (OAL), offering disease control with minimal toxicity. However, the clinical outcomes and safety profile of ULD-RT remain inconsistently reported across studies. Methods: We conducted a systematic review of peer-reviewed studies evaluating ULD-RT in patients with OAL, including prospective, retrospective, and comparative cohorts published between 2000 and 2025. A comprehensive search was performed in PubMed, Embase, and Scopus. Eligible studies reported clinical outcomes (e.g., response rates, local control, progression-free survival) and safety data (acute and late toxicities). Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Results: Ten studies comprising 591 patients met the inclusion criteria. The overall response rate to ULD-RT ranged from 88% to 100%, with complete response rates of 50% to 95%. Local control rates ranged from 63% to 100%, and 2-year progression-free survival exceeded 85% in most studies. Importantly, no grade ≥ 3 toxicities were observed following the regimen of 4 Gy in two fractions. Acute toxicities occurred in up to 42% of patients, typically grade 1 dry eye or conjunctivitis. Late toxicities were uncommon (16–33%), with cataracts rarely requiring surgery. All included studies were rated as good quality (NOS score ≥ 7), indicating low risk of bias. Conclusions: ULD-RT is a highly effective and safe treatment modality for OAL, providing excellent local control with a favorable toxicity profile. These findings support the adoption of ULD-RT as a first-line radiotherapy strategy for indolent OAL. Future prospective trials with longer follow-up and standardized toxicity reporting are warranted to confirm and refine its clinical role.

28 March 2024 in Cureus
Verified
Journal Article
Open access
PDF file
MRMarija Zivkovic Radojevic
Marija Zivkovic Radojevic
NMNeda Milosavljević
Neda Milosavljević
SJSlobodan Jankovic
Slobodan Jankovic
Miloš GrujićMiloš Grujić
Miloš Grujić
KJKatarina Janković
Katarina Janković
MFMarko Folić
Marko Folić
Objective: To analyze the level of fear and anxiety related to radiotherapy in oncology patients treated before and during the COVID-19 pandemic, as well as to examine whether the advancement of radiotherapy centers leads to any reduction in the patient's fear in emergency situations. Methods: Two cross-sectional studies were conducted in two time frames (2016 and 2022) based on the analysis of the intensity of anxiety and fear of radiotherapy in oncology patients with assistance. A questionnaire for assessing fear of radiotherapy in oncology patients and Zung's and Beck's self-reported anxiety scales were used. The first part of the research integrated all data of research interest obtained from patients treated with radiotherapy during 2016, and the second cross-sectional study included all patients treated in 2022 during the COVID-19 pandemic. The study was prepared according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist. Results: The first cross-sectional study had 154 participants who had been treated with radiotherapy, while in the second study, there were 159 patients. Patients treated in 2022 show significantly higher levels of fear and anxiety. External beam radiotherapy and brachytherapy simultaneously used in both studies increased the level of fear and anxiety. Conclusion: The conducted research showed exceptional differences in the intensity of fear and anxiety in patients treated with radiotherapy in different health situations, as was the case during the COVID-19 pandemic, with a significant impact on the stability of the health system and the challenges to providing standard services.

26 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MPMarija Peulic
Marija Peulic
RZRadica Zivkovic Zaric
Radica Zivkovic Zaric
MSMilorad Stojadinovic
Milorad Stojadinovic
MPMiodrag Peulic
Miodrag Peulic
JGJagoda Gavrilovic
Jagoda Gavrilovic
NMNeda Milosavljevic
Neda Milosavljevic
Background/Objectives: Drug prescribing in elderly people with chronic diseases carries certain risks. The desire to treat several different diseases at the same time increases the risk of inadequate drug prescribing. Prostate cancer is a disease of older men and occurs in most men over the age of 65. With age, the risk of prostate cancer increases, but so does the risk of the inadequate prescription of drugs. Our research aimed to highlight the potential inadequate prescription of drugs in patients with prostate cancer, considering that it is mostly a population of older men in whom a greater number of comorbidities is expected, followed by the use of a greater number of drugs. Methods: Our investigation was designed as an observational, cross-sectional study of 334 male patients who presented at the Multidisciplinary Tumor Board (MDT) for urological cancers at the University Clinical Center Kragujevac, Kragujevac, Serbia, from 1 September to 15 December 2023. Our primary outcome was obtaining the MAI score. Results: Our study showed that a significant number of drugs per patient with a prostate cancer diagnosis were prescribed potentially inadequately. The factors associated with greater risk for PIP were the initial level of PSA, ADT meta (intermittent), and several prescribed drugs; on the other hand, secondary hormonal therapy was the reason for less frequent PIP. Conclusions: In conclusion, patients with prostate cancer are under increased risk of inappropriate prescribing when they are prescribed more medication, have high PSA, and have ADT meta (intermittent). To stop the incidence of inappropriate prescribing and its serious economic and health consequences, clinicians should take special care when prescribing new drugs to such patients.

22 January 2026 in Cureus
Verified
Journal Article
Open access
MRMarija Živković Radojević
Marija Živković Radojević
KBKsenija Bosnjakovic
Ksenija Bosnjakovic
NMNeda Milosavljević
Neda Milosavljević
Miloš GrujićMiloš Grujić
Miloš Grujić
MTMilos Todorovic
Milos Todorovic
Medical errors represent an inherent risk in all areas of medicine, but in radiation oncology, they are of particular concern due to the complexity of treatment pathways and the potential severity of consequences. While legal systems often equate medical error with negligent treatment, clinicians typically view medical error as an unintended deviation occurring despite adherence to accepted standards of care. This conceptual discrepancy contributes to fear-driven practice, underreporting of adverse events, and missed opportunities for system-level learning. In this in-depth review, we synthesize current evidence on the definitions, mechanisms, and classification of medical errors, with a specific focus on radiation oncology. We critically analyze error patterns across pre-treatment, treatment, and post-treatment phases, emphasizing the interplay between human factors, system vulnerabilities, and technological complexity. Beyond technical considerations, this review provides a novel integrative perspective by linking guideline-based practice, incident learning systems, safety culture, communication strategies, and emerging artificial intelligence-assisted quality assurance approaches. Using Serbia as an illustrative example of a developing country, we highlight how legal frameworks centered predominantly on criminal liability, combined with high clinical workload and limited national reporting systems, may inadvertently discourage transparency and learning from errors. We propose a multidimensional safety framework that integrates protocol harmonization, non-punitive reporting, structured error disclosure, clinician support mechanisms, and advanced technological solutions. By shifting the focus from individual blame to system-based prevention and resolution, this review offers transferable insights for improving patient safety, enhancing clinician well-being and strengthening safety culture in radiation oncology across diverse healthcare settings.

30 August 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MRMarija Živković Radojević
Marija Živković Radojević
NMNeda Milosavljević
Neda Milosavljević
SJSlobodan Janković
Slobodan Janković
Miloš GrujićMiloš Grujić
Miloš Grujić
KJKatarina Janković
Katarina Janković
MFMarko Folić
Marko Folić